{"product_id":"vcel-vrio-analysis","title":"Vericel Corporation (VCEL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the sustainable competitive advantage of Vericel Corporation (VCEL) hinges on a rigorous VRIO analysis. Discover immediately whether its core resources are truly Valuable, Rare, Inimitable, and Organized to exploit - the four pillars determining long-term market success. Dive into the findings below to see the strategic implications for Vericel Corporation (VCEL)'s future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: MACI Product Franchise Dominance (Sports Medicine)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of Vericel Corporation's current success, the MACI franchise, and how its unique structure creates a moat against competitors. Honestly, the numbers from Q3 2025 clearly show this is where the action is.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Drives the majority of revenue\u003c\/h3\u003e\n\u003cp\u003eThe MACI product line is clearly the primary value driver for Vericel Corporation. For the third quarter of fiscal 2025, MACI net revenue hit \u003cstrong\u003e$55.7 million\u003c\/strong\u003e, representing a strong \u003cstrong\u003e25%\u003c\/strong\u003e growth year-over-year. This single product line makes up the bulk of the company's total Q3 2025 revenue of \u003cstrong\u003e$67.5 million\u003c\/strong\u003e. The introduction of MACI Arthro instruments is accelerating this, with early data suggesting a higher conversion rate for implanting surgeons.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the revenue contribution:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: Specific cell therapy scaffold technology\u003c\/h3\u003e\n\u003cp\u003eThe specific cell therapy scaffold technology underpinning MACI is not something a competitor can easily replicate off the shelf. MACI is described as a first-in-class product that uses the patient's own chondrocytes. This personalized, biological approach creates inherent scarcity compared to off-the-shelf alternatives. What this estimate hides is the difficulty in scaling the patient-specific manufacturing process reliably.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High due to complex biological processes and regulatory hurdles\u003c\/h3\u003e\n\u003cp\u003eReplicating MACI is tough because it involves complex biological processes and navigating significant regulatory pathways with the U.S. Food and Drug Administration (FDA). The need to manage autologous (patient's own cells) processing introduces variability and high quality control barriers that competitors must overcome. The regulatory hurdles alone act as a massive time and capital sink for any potential challenger.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Strong, evidenced by sales force expansion\u003c\/h3\u003e\n\u003cp\u003eVericel Corporation appears well-organized to capitalize on the MACI franchise's success. A key indicator is the sales force expansion, which is on track for completion in the fourth quarter of 2025. This expansion moves the force from 76 to approximately \u003cstrong\u003e100 territories\u003c\/strong\u003e, positioning them to support anticipated volume growth starting in 2026.\u003c\/p\u003e\n\u003cp\u003eKey organizational strengths supporting MACI:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSales force expansion nearing \u003cstrong\u003e100\u003c\/strong\u003e territories completion.\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e800\u003c\/strong\u003e MACI Arthro surgeons trained to date.\u003c\/li\u003e\n\u003cli\u003eMACI Ankle clinical study initiation on track for Q4 2025.\u003c\/li\u003e\n\u003cli\u003eStrong operating cash flow of \u003cstrong\u003e$22.1 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained, based on market adoption and product differentiation\u003c\/h3\u003e\n\u003cp\u003eThe combination of a differentiated, hard-to-replicate product (Rarity\/Imitability) that is currently driving significant revenue (Value) and is backed by an expanding commercial structure (Organization) points toward a sustained competitive advantage. The high conversion rate seen in MACI Arthro implanting surgeons suggests deep market adoption and differentiation are locking in future revenue streams. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Burn Care Portfolio (Epicel and NexoBrid)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvides a stable, high-growth segment; Burn Care net revenue was \u003cstrong\u003e$11.8 million\u003c\/strong\u003e in Q3 2025, an increase of \u003cstrong\u003e21%\u003c\/strong\u003e sequentially over the second quarter of 2025. NexoBrid revenue reached \u003cstrong\u003e$1.5 million\u003c\/strong\u003e in Q3 2025, representing record quarterly revenue since launch, with growth of \u003cstrong\u003e38%\u003c\/strong\u003e versus the prior year and \u003cstrong\u003e26%\u003c\/strong\u003e versus the prior quarter. Epicel revenue in Q3 2025 was \u003cstrong\u003e$10.4 million\u003c\/strong\u003e, the highest quarter of the year and one of its highest to date.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eQ3 2025 Gross margin for the company was \u003cstrong\u003e73.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net income was \u003cstrong\u003e$5.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Non-GAAP adjusted EBITDA was \u003cstrong\u003e$17.0 million\u003c\/strong\u003e, or \u003cstrong\u003e25%\u003c\/strong\u003e of revenue.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Operating cash flow was \u003cstrong\u003e$22.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and investments as of September 30, 2025, totaled \u003cstrong\u003e$185 million\u003c\/strong\u003e with no debt.\u003c\/li\u003e\n\u003cli\u003eTotal full-year revenue guidance for 2025 is \u003cstrong\u003e$272 to $276 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nEpicel is a permanent skin replacement indicated for adult and pediatric patients with deep dermal or full thickness burns comprising a total body surface area greater than or equal to \u003cstrong\u003e30%\u003c\/strong\u003e. NexoBrid has an exclusive license for commercialization in North America from MediWound.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eEpicel\u003c\/th\u003e\n\u003cth\u003eNexoBrid\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication (TBSA)\u003c\/td\u003e\n\u003ctd\u003eBurns $\\ge$ \u003cstrong\u003e30%\u003c\/strong\u003e TBSA\u003c\/td\u003e\n\u003ctd\u003eEschar removal in adults and pediatric patients with deep partial-thickness and\/or full-thickness thermal burns\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Approval Year (Initial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2007\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAdults: December \u003cstrong\u003e28, 2022\u003c\/strong\u003e; Pediatric: August \u003cstrong\u003e15, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Feature\u003c\/td\u003e\n\u003ctd\u003ePermanent skin covering; Autologous treatment\u003c\/td\u003e\n\u003ctd\u003eTopically-administered biological product containing proteolytic enzymes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate for Epicel's established use, being FDA approved in \u003cstrong\u003e2007\u003c\/strong\u003e. High for NexoBrid due to the exclusive North American license. The initial license term provided exclusivity for the first \u003cstrong\u003efive years\u003c\/strong\u003e, with an option to extend by an additional \u003cstrong\u003e24 months\u003c\/strong\u003e (exercised in May 2022).\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nEffective, as seen by record NexoBrid quarterly revenue of \u003cstrong\u003e$1.5 million\u003c\/strong\u003e in Q3 2025 and record third quarter total revenue of \u003cstrong\u003e$67.5 million\u003c\/strong\u003e. The company held \u003cstrong\u003e$185 million\u003c\/strong\u003e in cash and investments as of September 30, 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEpicel patient survival at hospital discharge in clinical databases was \u003cstrong\u003e84.4%\u003c\/strong\u003e (for mean TBSA of \u003cstrong\u003e67.5%\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eNexoBrid development involved a regulatory milestone payment of \u003cstrong\u003e$7.5 million\u003c\/strong\u003e to MediWound upon FDA approval.\u003c\/li\u003e\n\u003cli\u003eTotal potential milestone payments for NexoBrid sales are up to \u003cstrong\u003e$125.0 million\u003c\/strong\u003e, with the first triggered when annual net sales exceed \u003cstrong\u003e$75.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary, unless the NexoBrid license term is very long-dated, as the initial exclusive supply term is \u003cstrong\u003efive years\u003c\/strong\u003e plus an option for \u003cstrong\u003e24 months\u003c\/strong\u003e. Epicel is the only treatment of its type approved by the FDA for use in the United States.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Proprietary Cell Therapy Manufacturing Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eProprietary Cell Therapy Manufacturing Infrastructure\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Underpins product supply and quality, crucial for maintaining high gross margins (\u003cstrong\u003e73.5%\u003c\/strong\u003e in Q3 2025). \u003cstrong\u003eRarity\u003c\/strong\u003e: Specialized, validated, and scalable cell therapy production is scarce.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Very high; requires massive capital, expertise, and regulatory validation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Improving; construction complete, with commercial manufacturing in the new Burlington facility expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained, as the new facility will support long-term growth.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe new facility is a state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility in Burlington, Massachusetts.\u003c\/li\u003e\n\u003cli\u003eThe facility includes approximately \u003cstrong\u003e125,000 square feet\u003c\/strong\u003e of manufacturing, laboratory, and office space.\u003c\/li\u003e\n\u003cli\u003eThe building development cost was estimated around \u003cstrong\u003e$200 million\u003c\/strong\u003e (shared with The Broad Institute).\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 gross margin guidance is reaffirmed at \u003cstrong\u003e74%\u003c\/strong\u003e, with Q4 2025 expected gross margin at approximately \u003cstrong\u003e77%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e125,000 square feet\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eManufacturing, lab, and office space in Burlington\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Cost (Shared Bldg)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEstimated cost for the building housing Vericel and Broad Institute\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eActual result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2025 Gross Margin Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReaffirmed guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2025 Expected Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Operating Expenses related to Facility\u003c\/td\u003e\n\u003ctd\u003eIncluded in \u003cstrong\u003e$46.1 million\u003c\/strong\u003e total\u003c\/td\u003e\n\u003ctd\u003eCosts included depreciation and MACI tech transfer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe facility is designed to meet existing \u003cstrong\u003eLEED Gold\u003c\/strong\u003e and \u003cstrong\u003eFitwel Level 2\u003c\/strong\u003e certifications.\u003c\/li\u003e\n\u003cli\u003eThe company reported \u003cstrong\u003e$185 million\u003c\/strong\u003e in cash and investments as of Q3 2025, with no debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Deeply Embedded Surgeon Training and Adoption Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates to sales volume; over \u003cstrong\u003e800\u003c\/strong\u003e MACI Arthro surgeons trained by Q3 2025.\u003c\/p\u003e\n\u003cp\u003eThe value is evidenced by financial results following surgeon adoption:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\/Rate\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Net Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The established network and experience level are unique to Vericel Corporation.\u003c\/p\u003e\n\u003cp\u003eThe pace of network establishment shows rarity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrained Surgeons (End of 2024): \u003cstrong\u003e150+\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrained Surgeons (Early May 2025): \u003cstrong\u003e400\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrained Surgeons (July 2025): Approximately \u003cstrong\u003e600\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrained Surgeons (Q3 2025): Over \u003cstrong\u003e800\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; requires years of relationship building and clinical education.\u003c\/p\u003e\n\u003cp\u003eThe adoption metrics for trained surgeons indicate embedded utilization:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBiopsy Growth for Trained Surgeons (YTD Q1 2025): Over \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMACI Implants for small condyle defects increase (Q2 2025 vs prior year): More than \u003cstrong\u003e40%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMACI implants for trochlea defects account for: Nearly \u003cstrong\u003e20%\u003c\/strong\u003e of MACI Arthro implants to date\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Excellent, demonstrated by continued surgeon training and adoption metrics.\u003c\/p\u003e\n\u003cp\u003eOrganizational execution is reflected in financial guidance and operational scaling:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eGuidance\/Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Total Revenue Guidance (Reaffirmed Nov 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$272 million to $276 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Gross Margin Guidance (Reaffirmed May 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Sales Force Expansion\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e76\u003c\/strong\u003e to approximately \u003cstrong\u003e100\u003c\/strong\u003e territories\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Revenue (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as relationships are sticky in medical device adoption.\u003c\/p\u003e\n\u003cp\u003eThe sticky nature is supported by the growth trajectory:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMACI Revenue Growth (YoY Q3 2025): \u003cstrong\u003e25%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMACI Revenue Growth (YoY Q2 2025): \u003cstrong\u003e21%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMACI Revenue Growth (YoY Q1 2025): \u003cstrong\u003e15%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Exceptional Profitability and Margin Structure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High profitability allows reinvestment and signals operational efficiency; full-year gross margin guidance is \u003cstrong\u003e74%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A gross margin near \u003cstrong\u003e74%\u003c\/strong\u003e in cell therapy is rare outside of established players. The last twelve months gross margin was reported at \u003cstrong\u003e73.81%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires process mastery to achieve this level consistently.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Highly organized to control costs, evidenced by Adjusted EBITDA margin hitting \u003cstrong\u003e25%\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if manufacturing efficiencies scale with volume.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key profitability metrics from the third quarter of 2025 and full-year 2025 guidance:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Actual\u003c\/th\u003e\n\u003cth\u003eFull-Year 2025 Guidance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$272 to $276 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOperational and financial achievements supporting this structure include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMACI® net revenue for Q3 2025 was \u003cstrong\u003e$55.7 million\u003c\/strong\u003e, reflecting \u003cstrong\u003e25%\u003c\/strong\u003e growth.\u003c\/li\u003e\n\u003cli\u003eBurn Care net revenue for Q3 2025 was \u003cstrong\u003e$11.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRecord third-quarter operating cash flow reached \u003cstrong\u003e$22.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and investments totaled \u003cstrong\u003e$185 million\u003c\/strong\u003e as of September 30, 2025, with no debt.\u003c\/li\u003e\n\u003cli\u003eMid-term targets include a gross margin in the \u003cstrong\u003ehigh-70% range\u003c\/strong\u003e and an adjusted EBITDA margin in the \u003cstrong\u003ehigh-30% range\u003c\/strong\u003e by 2029.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Robust Balance Sheet and Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a buffer against R\u0026amp;D delays and supports strategic growth; cash and investments stood at \u003cstrong\u003e$185 million\u003c\/strong\u003e with \u003cstrong\u003eno debt\u003c\/strong\u003e as of \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRecord third quarter Operating Cash Flow of \u003cstrong\u003e$22.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGAAP Net Income of \u003cstrong\u003e$5.1 million\u003c\/strong\u003e for the quarter ended September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eFree Cash Flow of nearly \u003cstrong\u003e$20 million\u003c\/strong\u003e after \u003cstrong\u003e$2.6 million\u003c\/strong\u003e in capital expenditures for the quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Amount\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$185 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo debt as of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord for any third quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGAAP result for the quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-GAAP profitability metric.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Debt-free status with significant cash in the sector is uncommon.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of past financial discipline, not an inherent capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong financial management has clearly prioritized a clean balance sheet.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as cash reserves deplete over time without replenishment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Exclusive North American License for NexoBrid\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eExclusive North American License for NexoBrid\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eValue: Secures a monopoly for a specific, growing burn care treatment (eschar removal) in a key geography.\u003c\/li\u003e\n\u003cli\u003eRarity: Exclusive rights to a licensed orphan product are inherently rare.\u003c\/li\u003e\n\u003cli\u003eImitability: Very high; competitors cannot legally offer it in North America.\u003c\/li\u003e\n\u003cli\u003eOrganization: Effective in maximizing the asset, with Q3 2025 revenue growth of \u003cstrong\u003e38%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eCompetitive Advantage: Sustained, for the duration of the license agreement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNexoBrid Financial Performance Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Value\u003c\/th\u003e\n\u003cth\u003eGrowth vs. Prior Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexoBrid Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBurn Care Net Revenue (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexoBrid Sequential Growth\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e26%\u003c\/strong\u003e (vs. Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eNexoBrid is a biological orphan product indicated for eschar removal in adults and pediatric patients with deep partial-thickness and\/or full-thickness thermal burns.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 NexoBrid revenue of \u003cstrong\u003e$1.5 million\u003c\/strong\u003e represented its highest quarterly revenue since launch.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Burn Care net revenue of \u003cstrong\u003e$11.8 million\u003c\/strong\u003e consisted of \u003cstrong\u003e$10.4 million\u003c\/strong\u003e of Epicel revenue and \u003cstrong\u003e$1.5 million\u003c\/strong\u003e of NexoBrid revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Advanced Clinical Development Pipeline (MACI Ankle)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates future revenue potential beyond current indications; FDA IND clearance received for the MACI Ankle study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having an advanced, late-stage indication expansion for a core product is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires successful R\u0026amp;D execution and regulatory navigation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Focused; study initiation is on track for Q4 2025. FDA IND clearance received for the Phase 3 MACI Ankle Clinical Study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, until the indication is approved and commercialized.\u003c\/p\u003e\n\u003cp\u003eThe potential value is supported by the high incidence of relevant injuries and the established revenue base of the core MACI product:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUp to \u003cstrong\u003e2 million\u003c\/strong\u003e acute ankle sprains occur each year in the United States.\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e50%\u003c\/strong\u003e of acute ankle sprains are estimated to result in some form of cartilage injury.\u003c\/li\u003e\n\u003cli\u003eChondral and\/or osteochondral lesions of the talus (OLT) are observed on arthroscopy after \u003cstrong\u003e65%\u003c\/strong\u003e of ankle fractures.\u003c\/li\u003e\n\u003cli\u003eMACI net revenue for Q3 2025 was \u003cstrong\u003e$55.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMACI net revenue for Q2 2025 was \u003cstrong\u003e$53.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-Year 2024 MACI net revenue was \u003cstrong\u003e$197.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe MASCOT (NCT06915233) clinical trial details provide further context on the development effort:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Name\/ID\u003c\/td\u003e\n\u003ctd\u003eMASCOT (NCT06915233)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication Target\u003c\/td\u003e\n\u003ctd\u003eSymptomatic Chondral or Osteochondral Defects of the Ankle (Talus)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSponsor\u003c\/td\u003e\n\u003ctd\u003eVericel Corporation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Subjects Planned\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e309\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubject Age Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17\u003c\/strong\u003e to \u003cstrong\u003e65\u003c\/strong\u003e Years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRandomization Ratio (MACI:BMS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2:1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Cell Density (per cm²)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e500,000 to 1,000,000\u003c\/strong\u003e cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Implant Composition\u003c\/td\u003e\n\u003ctd\u003eAutologous cultured chondrocytes on porcine collagen membrane\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Lesion Size for Eligibility\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e≥ 1.2 cm²\u003c\/strong\u003e on the talus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Recruiting Start\u003c\/td\u003e\n\u003ctd\u003eLate \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe core MACI product's composition involves specific cell density metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEach MACI implant consists of a small cellular sheet containing \u003cstrong\u003e500,000 to 1,000,000 cells per square centimetre\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVericel Corporation (VCEL) - VRIO Analysis: Proven Ability to Scale Commercial Operations\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures the company can capture market demand; expected full-year revenue growth is 20% to 23%. Reaffirmed full-year total revenue guidance of $272 million to $276 million. Q3 2025 Total net revenue was $67.5 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Many biotech firms struggle to scale sales and operations simultaneously.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires successful hiring, training, and territory management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong, as evidenced by the planned completion of MACI sales force expansion in the fourth quarter of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if the scaling process continues to be managed efficiently.\u003c\/p\u003e\n\u003cp\u003eKey Scaling and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Result\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Result\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMACI Net Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganization Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMACI sales force expansion on track to be completed in the fourth quarter of 2025, with all new hires to be in territories to start the year in 2026.\u003c\/li\u003e\n\u003cli\u003eMACI sales force expansion from 76 to approximately 100 territories.\u003c\/li\u003e\n\u003cli\u003eMore than 800 MACI Arthro surgeons trained to date as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2025, the Company had approximately $164 million in cash and investments, and no debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: Draft 13-week cash view by Friday. Trailing Twelve Months (TTM) Free Cash Flow ended in September 2025 was \u003cstrong\u003e$20.4 Mil\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516275286165,"sku":"vcel-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vcel-vrio-analysis.png?v=1740228610","url":"https:\/\/dcf-model.com\/pt\/products\/vcel-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}